Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We use our state-of-the-art dedicated workflow for designing focused libraries for receptors.
Fig. 1. The sreening workflow of Receptor.AI
The method involves detailed molecular simulations of the receptor in its native membrane environment, with ensemble virtual screening focusing on its conformational mobility. When dealing with dimeric or oligomeric receptors, the whole functional complex is modelled, and the tentative binding pockets on and between the subunits are established to address all possible mechanisms of action.
Key features that set our library apart include:
partner
Reaxense
upacc
O95633
UPID:
FSTL3_HUMAN
Alternative names:
Follistatin-like protein 3; Follistatin-related gene protein
Alternative UPACC:
O95633; A8K7E3
Background:
Follistatin-related protein 3, also known as Follistatin-like protein 3 or Follistatin-related gene protein, plays a pivotal role in various biological processes. It functions as a binding and antagonizing protein for members of the TGF-beta family, such as activin, BMP2, and MSTN. This protein is involved in bone formation, inhibiting osteoclast differentiation, and plays a crucial role in hematopoiesis by enhancing hematopoietic cell adhesion to fibronectin and facilitating the adhesion of hematopoietic precursor cells to the bone marrow stroma.
Therapeutic significance:
Understanding the role of Follistatin-related protein 3 could open doors to potential therapeutic strategies.